" class="no-js "lang="en-US"> Kenneth T. Mills - Medtech Alert
Sunday, April 14, 2024
Kenneth T. Mills

Kenneth T. Mills

About Kenneth T. Mills

Ken Mills is the founding President and Chief Executive Officer of REGENXBIO. Prior to REGENXBIO, Mr. Mills was the Chief Financial Officer and Vice President of Business Development at Meso Scale Diagnostics, a privately held life sciences company. There, he served as a member of the founding management team, and worked to establish the company’s operations and ongoing business strategy. In this position, Mr. Mills supervised all company activities, including direct management of corporate and business development, strategic planning, finance and accounting activities. Prior to Meso Scale Diagnostics, he was Director of Business Development for IGEN International, a medical diagnostics company. Mr. Mills received an S.B. in chemistry from the Massachusetts Institute of Technology.

Related Story

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

January 23 2023

REGENXBIO today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment […]

AbbVie and REGENXBIO Announce Eye Care Collaboration

September 14 2021

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and […]